Posted by Michael Wonder on 05 Nov 2019
FDA verdict on Biogen’s Alzheimer’s drug likely to be a ‘political decision,’ analyst says
4 November 2019 - Federal regulators may buckle to public and political pressure to approve Biogen’s experimental Alzheimer’s drug, according to Jefferies’ Michael Yee.
Federal regulators may buckle to public and political pressure to approve Biogen’s experimental Alzheimer’s drug, aducanumab, Jefferies’ Michael Yee told CNBC on Monday.
The Food and Drug Administration’s verdict, expected in 2020, “will come down to a political decision, in our opinion,” said Yee, an analyst who covers the biotech sector, on “The Exchange.”
